psalexa
P&S Market Research - A market research firm

Bile Duct Cancer Therapeutics Market

Global Bile Duct Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10903
Available Format:

The global bile duct cancer therapeutics market is expected to witness noticeable growth, in the near future, owing to increasing awareness about cancer and advancements in technologies for cancer treatment. Also, the increasing incidence of cancer is driving the bile duct cancer therapeutics market, globally.

Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma). The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief. The bile duct cancer treatment market has significant unmet need, due to the safety profiles and inadequate efficacy of the existing market products. Therefore, the market offers vast potential for novel participants that can introduce drugs, which could reverse or halt the disease progression and simultaneously, offer good safety profiles and high efficacy.

The global bile duct cancer therapeutics market is being driven by advancement in technologies in the healthcare segment, and increase in prevalence of cancer patients. Also, pharmaceutical companies are emphasizing on R&D to come up with potential treatment for bile duct cancer (cholangiocarcinoma). However, high cost along with latest clinical trials and approvals are acting as major barriers for the global bile duct cancer therapeutics market.

The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.

Due to availability of various chemotherapeutic agents for bile duct cancer (cholangiocarcinoma) therapeutics, the market for chemotherapeutic agents is expected to contribute larger revenue to the global bile duct cancer therapeutics market. Innovative bile duct cancer (cholangiocarcinoma) therapeutics are likely to enter into the market, during the forecast period (2017-2023).

Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.

Some of the key players in the global bile duct cancer therapeutics market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme Therapeutics, Inc. among several others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry